By Alex Wolf ( July 20, 2016, 7:23 PM EDT) -- Biopharmaceutical company Celgene Corp. is infusing privately held Jounce Therapeutics Inc. with an upfront payment of $225 million, a $36 million equity investment and up to an additional $2.3 billion in future payments to jointly develop and commercialize immuno-oncology treatments for patients with cancer, according to an announcement Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.